Lifeward Ltd. Reports Q2 2025 Revenue Drop of 15% to $5.7M, Net Income Falls from $3.6M to Loss of $0.6M, EPS Decreases from $0.42 to -$0.07

Reuters
Aug 14
<a href="https://laohu8.com/S/LFWD">Lifeward Ltd</a>. Reports <a href="https://laohu8.com/S/QTWO">Q2</a> 2025 Revenue Drop of 15% to $5.7M, Net Income Falls from $3.6M to Loss of $0.6M, EPS Decreases from $0.42 to -$0.07

Lifeward Ltd., a global leader in medical technology, has announced its financial results for the second quarter of 2025. The company reported a revenue of $5.7 million, a decrease of $1.0 million, or approximately 15%, compared to $6.7 million in the same quarter of 2024. This quarter's revenue, however, marked an increase from the $5.0 million reported in the first quarter of 2025. The net loss for the second quarter of 2025 was $6.6 million, compared to a net loss of $4.3 million in the second quarter of 2024. On a non-GAAP basis, the adjusted net loss was $3.5 million for this quarter, compared to $3.6 million during the same period last year. In terms of liquidity, as of June 30, 2025, Lifeward had $5.1 million in unrestricted cash and cash equivalents, with no debt. Cash used in operations was $3.9 million for the quarter, an improvement from $5.6 million used in the second quarter of 2024, reflecting operational efficiencies and the closure of the Fremont facility. Lifeward has issued its financial guidance for the full year 2025, targeting revenue of $24-$26 million and a non-GAAP net loss of $12-$14 million. The company has strengthened its executive leadership with the appointment of Mark Grant as President and CEO and Almog Adar as CFO to drive strategic growth initiatives.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Lifeward Ltd. published the original content used to generate this news brief via GlobeNewswire (Ref. ID: GNW9512564-en) on August 14, 2025, and is solely responsible for the information contained therein.

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Most Discussed

  1. 1
     
     
     
     
  2. 2
     
     
     
     
  3. 3
     
     
     
     
  4. 4
     
     
     
     
  5. 5
     
     
     
     
  6. 6
     
     
     
     
  7. 7
     
     
     
     
  8. 8
     
     
     
     
  9. 9
     
     
     
     
  10. 10